Ribonucleic Acid Interference (RNAi) Technology Market Report 2026

The ribonucleic acid interference (rnai) technology market size has grown rapidly in recent years. It will grow from $4.43 billion in 2025 to $5.14 billion in 2026 at a compound annual growth rate (CAGR) of 15.9%. The growth in the historic period can be attributed to advancements in molecular biology research, early clinical success of rnai therapeutics, expansion of academic gene research programs, availability of robust screening libraries, growth of biotech innovation ecosystems.

The ribonucleic acid interference (rnai) technology market size is expected to see rapid growth in the next few years. It will grow to $9.19 billion in 2030 at a compound annual growth rate (CAGR) of 15.6%. The growth in the forecast period can be attributed to increasing commercialization of rnai-based drugs, rising investments in rare disease therapeutics, expansion of nanoparticle delivery technologies, growing pharmaceutical partnerships, increasing regulatory acceptance of gene-silencing treatments. Major trends in the forecast period include increasing adoption of gene silencing therapies, rising use of sirna-based drug platforms, growing integration of rnai in precision medicine, expansion of targeted genetic disease treatments, enhanced delivery system optimization.

The growing demand for targeted therapeutics is expected to drive the expansion of the ribonucleic acid interference (RNAi) technology market in the coming years. Targeted therapies are treatments designed to specifically target and inhibit molecular abnormalities in cancer or other diseases, improving treatment precision while reducing damage to healthy cells. The rising emphasis on targeted therapies is largely fueled by advancements in precision medicine, which allow for personalized and more effective treatments based on individual genetic profiles. Ribonucleic Acid Interference (RNAi) Technology boosts the demand for targeted therapeutics by enabling precise gene silencing for the treatment of genetic and rare diseases. It facilitates the development of highly specific and effective therapies, promoting innovation in personalized medicine. For example, in December 2024, according to the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit medical and scientific organization, the Food and Drug Administration (FDA) approved 6 gene therapy products in 2023, compared to 5 approvals in 2022. Thus, the increasing demand for targeted therapeutics is fueling the growth of the ribonucleic acid interference (RNAi) technology market.

Major companies operating in the ribonucleic acid interference (RNAi) technology market are concentrating on platform integration, including strategic funding and support, to streamline the development, delivery, and commercialization of RNA interference (RNAi) therapeutics, ensuring a sustainable pipeline of multiple programs across various disease areas. Strategic funding and support involves obtaining investment and resources from venture capital, industry partners, and other stakeholders to accelerate research, development, and commercialization of RNA interference (RNAi) therapeutics. For example, in October 2024, City Therapeutics Inc., a US-based biopharmaceutical company, secured $135 million in Series A financing led by ARCH Venture Partners, with participation from other prominent life sciences investors, to advance RNA interference (RNAi)-based medicine. This funding will support the development of RNAi-based therapies by utilizing its proprietary lipid nanoparticle (LNP) delivery platform, engineered to target tissues beyond the liver with high precision. The platform is designed to address a key historical limitation in the field, facilitating the creation of therapies for a broader range of genetic disorders.

In July 2023, Novartis AG, a Switzerland-based pharmaceutical company, acquired DTx Pharma Inc. for an undisclosed sum. Through this acquisition, Novartis AG intends to enhance its RNAi therapeutic capabilities and broaden its neuromuscular disease portfolio by leveraging DTx Pharma’s FALCON delivery platform. DTx Pharma Inc. is a US-based preclinical-stage biotechnology company focused on RNA interference (RNAi) technology for the development of RNAi-based therapeutics.

Major companies operating in the ribonucleic acid interference (rnai) technology market are F. Hoffmann-La Roche AG, Merck KGaA, Novartis AG, Thermo Fisher Scientific Inc., Danaher Corporation, Revvity Inc., QIAGEN N.V., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., GenScript Biotech Corporation, Promega Corporation, Arrowhead Pharmaceuticals Inc., Silence Therapeutics plc, Creative Biolabs Inc., Bioneer Corporation, Genevant Sciences Ltd., Gradalis Inc., Altogen Labs LLC, Sirnaomics Inc., Altogen Biosystems Inc.

North America was the largest region in the ribonucleic acid interference (RNAi) technology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ribonucleic acid interference (rnai) technology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ribonucleic acid interference (rnai) technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the rnai technology market by increasing costs of imported oligonucleotide synthesis equipment, lipid nanoparticle materials, laboratory reagents, and high-precision analytical instruments. North America and Europe are most affected due to dependence on specialized imported research tools, while Asia-Pacific faces cost pressure on contract research and manufacturing services. These tariffs are elevating research and development expenditures and influencing pricing of rnai-based therapies. However, they are also supporting domestic manufacturing of research reagents, regional capability building, and long-term resilience of genetic technology supply chains.

The ribonucleic acid interference (rnai) technology market research report is one of a series of new reports that provides ribonucleic acid interference (rnai) technology market statistics, including ribonucleic acid interference (rnai) technology industry global market size, regional shares, competitors with a ribonucleic acid interference (rnai) technology market share, detailed ribonucleic acid interference (rnai) technology market segments, market trends and opportunities, and any further data you may need to thrive in the ribonucleic acid interference (rnai) technology industry. This ribonucleic acid interference (rnai) technology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Ribonucleic acid interference (RNAi) technology is a biological process that controls gene expression by employing small RNA molecules to silence specific messenger RNA (mRNA) sequences. It is used to modulate gene activity, enabling scientists to silence or decrease the production of targeted proteins. It aids in inhibiting the expression of disease-related genes, making it a valuable tool for genetic research, drug development, and therapeutic applications.

The primary products of ribonucleic acid interference (RNAi) technology include micro ribonucleic acid (miRNA), small interfering ribonucleic acid (siRNA), and others. Micro ribonucleic acid (miRNA) consists of short, non-coding ribonucleic acid molecules that bind to complementary messenger ribonucleic acid sequences to suppress translation or induce degradation, thereby regulating gene expression. The delivery approaches include viral vectors, nanoparticles, chemical modifications, and physical methods, and they are applied in areas such as therapeutics, drug discovery, agriculture, and diagnostics. RNAi technology is extensively utilized by pharmaceutical and biotechnology companies, academic and research institutions, as well as contract research organizations (CROs) and contract manufacturing organizations (CMOs).

The ribonucleic acid interference (RNAi) technology consists of revenues earned by entities by providing services such as gene silencing services, custom ribonucleic acid (RNA) synthesis, oligonucleotide design, ribonucleic acid (RNA) sequencing, target validation, functional genomics screening, data analysis, drug discovery support, delivery system optimization, and molecular assay development. The market value includes the value of related goods sold by the service provider or included within the service offering. The RNA interference (RNAi) technology market also includes sales of microRNA mimics, transfection reagents, ribonucleic acid (RNA) delivery kits, plasmid vectors, assay kits, cell lines, reagents and buffers, and laboratory consumables. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.